Can engineered immune cells tackle an incurable childhood brain tumor?

NCT ID NCT05544526

Recruiting now ⭐️ CURE ⭐️ Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new type of cell therapy called GD2 CAR-T cells in children and young adults with diffuse midline glioma, a rare and aggressive brain tumor. The treatment involves collecting the patient's own immune cells, modifying them to recognize and attack the tumor, and infusing them back. The main goals are to see if the cells can be made successfully, if the treatment is safe, and how long the cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GD2 CAR T cells
What this could lead to: If successful, this could lead to a new treatment option for a currently incurable brain tumor in children, potentially improving survival.
What could go wrong: This is an early-phase trial with a small number of participants. The therapy may cause severe side effects, and its effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse midline glioma, H3 K27M-mutant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT

Contacts and locations

Locations

Great Ormond Street Hospital
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.